research JAK Inhibitors for Treatment of Alopecia Areata
JAK inhibitors can effectively reverse hair loss in people with alopecia areata.
Search
for
Sort by
Research
240-270 / 1000+ resultsresearch Precision Dermatology: A Review of Molecular Biomarkers and Personalized Therapies
Personalized medicine in dermatology uses molecular biomarkers to improve diagnosis and treatment but needs further advancements for practical use.
research Inactivated COVID-19 Vaccine Induces a Low Humoral Immune Response in a Subset of Dermatological Patients Receiving Immunosuppressants
Some patients on immunosuppressants had a weaker immune response to the Sinovac-CoronaVac COVID-19 vaccine.
research Regenerative Potential and Clinical Application of Mesenchymal Stem Cell-Derived Exosomes
MSC-derived exosomes can help treat COVID-19, hair loss, skin aging, and arthritis.
research Hidradenitis Suppurativa: A Practical Review of Possible Medical Treatments Based on Over 350 Hidradenitis Patients
Different treatments for Hidradenitis suppurativa range from antibiotics and hormonal therapies to surgery, depending on severity.
research Overview Of Alopecia Areata For Managed Care And Payer Stakeholders In The United States
Alopecia areata causes hair loss and life quality issues; current treatments are often unsatisfactory, but new drugs like JAK inhibitors show promise.
research Androgenetic Alopecia: An Update Of Treatment Options
Minoxidil is the only FDA-approved topical drug for treating male or female pattern hair loss, and other medications like finasteride and dutasteride can also increase hair growth.
research Increased Retinol-Binding Protein 4 and Anti-RBP4 Antibody in Alopecia Areata
People with alopecia areata have higher levels of RBP4 protein and antibodies against it.
research Topically Applied Nicotinamide Inhibits Human Hair Follicle Growth Ex Vivo
Nicotinamide applied to the scalp can slow down hair growth.
research Oxygen, Metabolism, and Regeneration: Lessons from Mice
Mice with enhanced regeneration abilities may help develop new regenerative medicine therapies.
research Low-Molecular-Weight Synthetic Antioxidants: Classification, Pharmacological Profile, Effectiveness, and Trends
Synthetic antioxidants are effective, cheap, and stable, with some like zinc and cholecalciferol reducing child and cancer deaths, but the safety of additives like BHA, BHT, TBHQ, and PEG needs more research.
research Cyclin-Dependent Kinase 4/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force Dermatology for Cancer Patients International Study
Skin side effects from CDK4/6 inhibitors in breast cancer patients are generally mild and treatable, allowing most patients to continue treatment.
research North American Clinical Management Guidelines for Hidradenitis Suppurativa: A Publication from the United States and Canadian Hidradenitis Suppurativa Foundations
There is no standardized treatment for hidradenitis suppurativa, and individualized plans are needed.
research New-Onset Systemic Lupus Erythematosus Beginning as Class V Lupus Nephritis After COVID-19 Vaccination
COVID-19 vaccination may trigger lupus in some people.
research Cardiovascular Effects of Hormone Therapy for Prostate Cancer
Hormone therapy for prostate cancer can increase heart risks, especially in men with heart conditions.
research Protein Degradation: Expanding the Toolbox to Restrain Cancer Drug Resistance
Using protein degradation to fight cancer drug resistance shows promise but needs more precise targeting and fewer side effects.
research Ideal JAK Inhibitor for Alopecia Areata: Baricitinib, Tofacitinib, Ritlecitinib, or Ifidancitinib - Revisiting the Immunomechanisms of the JAK Pathway
No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.
research Off-Label Uses of Retinoids in Dermatology
Retinoids are effective for various skin conditions and hair loss but have serious side effects, so low doses are recommended.
research Antiviral Drugs Prolong Survival in Murine Recessive Dystrophic Epidermolysis Bullosa
Antiviral drugs, especially daclatasvir, may be a new treatment for a rare skin disease, improving survival and reducing symptoms in mice.
research Hypoxia Induced Multipotent Stem Cell-Secreted Proteins Induce Hair Growth in a Phase 1a/2b Trial in Male Pattern Baldness
A trial showed that a new treatment is safe and effective for male pattern baldness, with most participants growing new hair.
research Oral Baricitinib Restores Hair Loss in Alopecia Areata
Baricitinib, a medication taken by mouth, was effective in regrowing hair for people with severe hair loss.
research Advances In The Mechanism And New Therapies Of Alopecia Areata
New treatments targeting the JAK signaling pathway, especially JAK inhibitors, show promise for alopecia areata.
research A Summary of In Vitro, Phase I, and Phase II Studies Evaluating the Mechanism of Action, Safety, and Efficacy of Clascoterone (Cortexolone 17a Propionate, CB-03-01) in Androgenetic Alopecia
Clascoterone safely promotes hair growth similar to minoxidil.
research Combination Therapies and the Theoretical Limits of Evidence-Based Medicine
The current system can't fully test all combination treatments, so alternative methods and regulatory flexibility are needed.
research Dutasteride
Dutasteride effectively treats enlarged prostate, reduces prostate cancer risk, and promotes hair regrowth with few side effects.
research Expecting Scalp Hair Regrowth During Severe Alopecia Areata Treatment with Baricitinib: Insights from Patient Trajectories in Phase III Trials
Hair regrowth from severe alopecia areata treatment with baricitinib can vary, with faster results in those with shorter hair loss duration.
research Setipiprant for Androgenetic Alopecia in Males: Results from a Randomized, Double-Blind, Placebo-Controlled Phase 2a Trial
Setipiprant did not significantly improve hair growth in men with hair loss.
research Non-Clinical Safety Evaluation and Risk Assessment of Aleglitazar, a Dual PPAR α/γ Agonist, and Its Major Human Metabolite
Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.
research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
research Integrated Safety Analysis of Baricitinib in Adults With Severe Alopecia Areata From Two Randomized Clinical Trials
Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.